Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast ...

Maintaining regulatory compliance within bulk plants can be a challenge. P3 Propane Safety’s bulk plant system is designed to ...

Q4 2024 Earnings Call Transcript March 27, 2025 P3 Health Partners Inc. misses on earnings expectations. Reported EPS is ...

Lake Street analyst Brooks O’Neil maintained a Buy rating on P3 Health Partners (PIII – Research Report) today and set a price target of $1.00.